Nivolumab in Metastatic Non–Small Cell Lung Cancer
Andrea Deel, PharmD
Kingsport Hematology Oncology, Kingsport, Tennessee
Andrea Deel, PharmD, Kingsport Hematology Oncology, 4485 West Stone Drive, Suite 200, Kingsport TN 37660. E-mail: email@example.com
Author’s disclosures of potential conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2016;7:220–225 |
doi: 10.6004/jadpro.2016.7.2.7 |
© 2016 Harborside Press®
Research into the PD-1 pathway has been shown to be valuable in the immune system’s ability to control cancer. Blocking this pathway with targeted therapies such as nivolumab has led to tumor response and control in some patients with non–small cell lung cancer. Learn about this recently approved agent, including the most important facts necessary for successful management of patients on this therapy.
For access to the full length article, please sign in